06 May 2024
06 May 2024
Amgen announced updates in the obesity space, with topline data for MariTide expected in late 2024.
The centre of gravity in the pharmaceutical industry is changing. But one common factor can help make supply chains more comprehensible, resilient and valuable: data
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
The assay development phase is expected to complete by early 2025.
The FDA has awarded the designation following a review of initial safety and efficacy data from two Phase I/II clinical trials.
Despite failing to get an approval for type 1 diabetes in 2019, Lexicon plans to resubmit its NDA to the FDA by mid-2024.
Techniques such as rapid nanomotion-based susceptibility testing, and MALDI-TOF-MS could be used to identify resistance mechanisms of several deadly organisms.
From nanoparticles to transdermal patches, Pharmaceutical Technology takes a look at the latest in drug delivery technologies for women's health.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
